BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barror S, Avramovic G, Oprea C, Surey J, Story A, Macías J, Cullen W, Crowley D, Horan A, Naughton AM, Iglesias M, Ianache I, Lazar S, Popa I, McHugh T, Menezes D, Tinago W, Lambert JS. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. J Antimicrob Chemother 2019;74:v39-46. [PMID: 31782499 DOI: 10.1093/jac/dkz455] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Generaal E, Logtenberg van der Grient H, Schatz E, van Santen DK, Boyd A, Woods SK, Baak BLC, Prins M. A Feasibility Study to Increase Chronic Hepatitis C Virus RNA Testing and Linkage to Care among Clients Attending Homeless Services in Amsterdam, The Netherlands. Diagnostics (Basel) 2021;11:1197. [PMID: 34209440 DOI: 10.3390/diagnostics11071197] [Reference Citation Analysis]
2 Valencia J, Lazarus JV, Ceballos FC, Troya J, Cuevas G, Resino S, Torres-Macho J, Ryan P. Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care. Liver Int 2021. [PMID: 34767680 DOI: 10.1111/liv.15095] [Reference Citation Analysis]
3 A H, L M, Am J, M M, Gp A, S V. Community-Based Assessment and Treatment of Hepatitis C Virus-Related Liver Disease, Injecting Drug and Alcohol Use Amongst People Who Are Homeless: A Systematic Review and Meta-Analysis. Int J Drug Policy 2021;:103342. [PMID: 34210551 DOI: 10.1016/j.drugpo.2021.103342] [Reference Citation Analysis]
4 Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019;286:503-25. [PMID: 31472002 DOI: 10.1111/joim.12972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
5 Conway B, Rodriguez-tajes S, Garcia-retortillo M, Pérez-hernandez P, Teti E, Ryan P, Fraser C, Macedo G, Morano Amado LE, Lédinghen VD, Fenech M, Martins A, Guerra-veloz MF, Ntalla I, Ramroth H, Vanstraelen K, Hernandez C, Mertens M, O’loan J. Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations. Future Virology. [DOI: 10.2217/fvl-2021-0266] [Reference Citation Analysis]
6 Busschots D, Kremer C, Bielen R, Koc ÖM, Heyens L, Dercon E, Verrando R, Windelinckx T, Maertens G, Bourgeois S, Hens N, Matheï C, Robaeys G. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. Harm Reduct J 2021;18:54. [PMID: 34001145 DOI: 10.1186/s12954-021-00502-7] [Reference Citation Analysis]
7 Seaman A, King CA, Kaser T, Geduldig A, Ronan W, Cook R, Chan B, Levander XA, Priest KC, Korthuis PT. A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment. Int J Drug Policy 2021;:103359. [PMID: 34325969 DOI: 10.1016/j.drugpo.2021.103359] [Reference Citation Analysis]
8 Schmidbauer C, Schwarz M, Schütz A, Schubert R, Schwanke C, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy. PLoS One 2021;16:e0252274. [PMID: 34086708 DOI: 10.1371/journal.pone.0252274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hashim A, Bremner S, Grove JI, Astbury S, Mengozzi M, O'Sullivan M, Macken L, Worthley T, Katarey D, Aithal GP, Verma S. Chronic liver disease in homeless individuals and performance of non-invasive liver fibrosis and injury markers: VALID study. Liver Int 2021. [PMID: 34846794 DOI: 10.1111/liv.15122] [Reference Citation Analysis]
10 Crowley D, Avramovic G, Cullen W, Farrell C, Halpin A, Keevans M, Laird E, McHugh T, McKiernan S, Miggin SJ, Murtagh R, Connor EO, O'Meara M, Reilly DO, Lambert JS. New hepatitis C virus infection, re-infection and associated risk behaviour in male Irish prisoners: a cohort study, 2019. Arch Public Health 2021;79:97. [PMID: 34103080 DOI: 10.1186/s13690-021-00623-2] [Reference Citation Analysis]
11 Connolly SP, Avramovic G, Cullen W, McHugh T, O'Connor E, Mc Combe G, Crowley D, Naughton AM, Horan A, Lambert JS. HepCare Ireland-a service innovation project. Ir J Med Sci 2021;190:587-95. [PMID: 32761548 DOI: 10.1007/s11845-020-02324-1] [Reference Citation Analysis]
12 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
13 Seaman A, Ronan W, Myers L, Wheelock H, Butler M, Nelson L, E. Williams B, Zaman A. Hepatitis C Treatment Among People Who Use Drugs in an Office-Based Opioid Treatment Program Versus a Syringe Exchange Program: A Real-World Prospective Clinical Trial. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.114781] [Reference Citation Analysis]